KR20230005978A - Ilt-결합제 및 이의 사용 방법 - Google Patents

Ilt-결합제 및 이의 사용 방법 Download PDF

Info

Publication number
KR20230005978A
KR20230005978A KR1020227042267A KR20227042267A KR20230005978A KR 20230005978 A KR20230005978 A KR 20230005978A KR 1020227042267 A KR1020227042267 A KR 1020227042267A KR 20227042267 A KR20227042267 A KR 20227042267A KR 20230005978 A KR20230005978 A KR 20230005978A
Authority
KR
South Korea
Prior art keywords
seq
chain variable
amino acid
variable region
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227042267A
Other languages
English (en)
Korean (ko)
Inventor
다나 옌 메이 두이
알렌 제임스 에벤스 제이알.
다니엘 데이비드 카플란
치아-잉 카오 람
칼야니 몬달
제프리 윌리엄 스톤
얀 왕
Original Assignee
엔지엠 바이오파마슈티컬스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔지엠 바이오파마슈티컬스, 아이엔씨. filed Critical 엔지엠 바이오파마슈티컬스, 아이엔씨.
Publication of KR20230005978A publication Critical patent/KR20230005978A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227042267A 2020-05-01 2021-04-29 Ilt-결합제 및 이의 사용 방법 Pending KR20230005978A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063019068P 2020-05-01 2020-05-01
US63/019,068 2020-05-01
US202063122848P 2020-12-08 2020-12-08
US63/122,848 2020-12-08
PCT/US2021/029866 WO2021222544A1 (en) 2020-05-01 2021-04-29 Ilt-binding agents and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20230005978A true KR20230005978A (ko) 2023-01-10

Family

ID=76012027

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227042267A Pending KR20230005978A (ko) 2020-05-01 2021-04-29 Ilt-결합제 및 이의 사용 방법

Country Status (17)

Country Link
US (2) US11802155B2 (https=)
EP (2) EP4691561A2 (https=)
JP (1) JP7834028B2 (https=)
KR (1) KR20230005978A (https=)
CN (2) CN115768524A (https=)
AU (1) AU2021265801B2 (https=)
BR (1) BR112022021684A2 (https=)
CA (1) CA3181197A1 (https=)
CL (1) CL2022003004A1 (https=)
CO (1) CO2022015208A2 (https=)
ES (1) ES3039441T3 (https=)
IL (1) IL297748A (https=)
MX (1) MX2022013466A (https=)
MY (1) MY209480A (https=)
PE (1) PE20221894A1 (https=)
TW (1) TW202206463A (https=)
WO (1) WO2021222544A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111867614A (zh) * 2018-01-18 2020-10-30 艾达奈特公司 抗lilrb抗体及其用途
JP7284256B2 (ja) 2019-08-12 2023-05-30 ビオンド バイオロジクス リミテッド Ｉｌｔ２に対する抗体およびその使用
JP2023537396A (ja) 2020-08-12 2023-08-31 ビオンド バイオロジクス リミテッド Ｉｌｔ２に対する抗体およびその使用
WO2023077521A1 (en) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023140875A1 (en) * 2022-01-19 2023-07-27 Ngm Biopharmaceuticals, Inc. Uses of ilt3-binding agents
IL315487A (en) * 2022-03-07 2024-11-01 Agenus Inc ANTI-ILT2 antibodies and their uses
WO2023170434A1 (en) 2022-03-11 2023-09-14 Macomics Limited Compositions and methods for modulation of macrophage activity
WO2023235706A1 (en) * 2022-05-31 2023-12-07 Ngm Biopharmaceuticals, Inc. Combination therapies using ilt-binding agents and pd-1 inhibitors
WO2024120526A1 (zh) * 2022-12-09 2024-06-13 诺纳生物（苏州）有限公司 抗ilt4抗体及其制备方法和应用
AU2023410277A1 (en) * 2022-12-23 2025-06-12 Iomx Therapeutics Ag Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
EP4491230A1 (en) * 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
WO2024218650A1 (en) * 2023-04-19 2024-10-24 Pfizer Inc. Lilrb1 and lilrb2 antibodies and methods of use thereof
WO2025059304A2 (en) * 2023-09-12 2025-03-20 Agenus Inc. Methods of treating cancer using ilt2 antibodies and combination therapies
GB202314087D0 (en) * 2023-09-14 2023-11-01 Macomics Ltd Biomarker for cancer
WO2025168070A1 (zh) * 2024-02-08 2025-08-14 东曜药业有限公司 一种抗ilt2/4单抗的制剂、包含其的药盒及其应用
WO2025191142A2 (en) 2024-03-15 2025-09-18 Les Laboratoires Servier Antibodies to lilrb1 and lilrb2 and compositions thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE456656T1 (de) 1996-12-06 2010-02-15 Schering Corp Isolierte gene aus säuger monozyten und betreffende reagentien
US20060078564A1 (en) 2002-05-08 2006-04-13 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US20040241167A1 (en) 2001-06-25 2004-12-02 Nicole Suciu-Foca Ilt3 and ilt4-related compositons and methods
WO2003000199A2 (en) 2001-06-25 2003-01-03 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
PL374463A1 (en) 2001-11-14 2005-10-17 Immunex Corporation Modulation of lir function to treat rheumatoid arthritis
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
CA2637786A1 (en) 2006-01-23 2007-08-16 President And Fellows Of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration
ES2437110T3 (es) 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
RU2010128608A (ru) 2007-12-11 2012-01-20 Дженентек, Инк. (Us) Модуляторы регенерации нейронов
CL2009001155A1 (es) 2008-05-13 2010-06-04 Genentech Inc Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas.
WO2009140361A1 (en) 2008-05-13 2009-11-19 Genentech, Inc. ANTI-PirB ANTIBODIES
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2014164519A1 (en) 2013-03-12 2014-10-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
CA2948871A1 (en) 2014-05-22 2015-11-26 Fred Hutchinson Cancer Research Center Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
WO2016044022A1 (en) 2014-09-16 2016-03-24 The Board Of Trustees Of The Leland Stanford Junior University Blocking pirb upregulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
US20180201676A1 (en) 2015-02-11 2018-07-19 University Health Network Methods and compositions for modulating lilr proteins
CA2977544C (en) 2015-03-06 2023-12-19 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017042814A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Use of perforin positive immature dendritic cells in disease treatment
US20190177391A1 (en) 2016-03-31 2019-06-13 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
WO2018027197A1 (en) 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CN111712518B (zh) 2017-11-17 2025-03-25 默沙东有限责任公司 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途
WO2019107387A1 (ja) 2017-11-28 2019-06-06 国立大学法人大阪大学 マラリア治療薬、マラリアの治療方法、マラリア治療用候補物質のスクリーニング方法、マラリア重症化マーカー、マラリアの重症化の危険度を試験する方法および試験試薬
EA202091540A1 (ru) 2017-12-22 2021-03-22 Джаунс Терапьютикс, Инк. Антитела к lilrb2
CN111867614A (zh) * 2018-01-18 2020-10-30 艾达奈特公司 抗lilrb抗体及其用途
CN113056483B (zh) 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
US20210301020A1 (en) 2018-07-24 2021-09-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
PH12022551462A1 (en) 2019-12-19 2023-11-13 Ngm Biopharmaceuticals Inc Ilt3-binding agents and methods of use thereof
CN114945594B (zh) 2019-12-23 2024-11-26 株式会社Lg化学 抗lilrb1抗体及其用途

Also Published As

Publication number Publication date
JP2023523628A (ja) 2023-06-06
EP4143229B1 (en) 2025-07-30
JP7834028B2 (ja) 2026-03-23
EP4143229A1 (en) 2023-03-08
CO2022015208A2 (es) 2023-01-16
WO2021222544A1 (en) 2021-11-04
US12410251B2 (en) 2025-09-09
US11802155B2 (en) 2023-10-31
AU2021265801B2 (en) 2026-04-02
BR112022021684A2 (pt) 2023-01-17
AU2021265801A1 (en) 2022-11-17
CN116589581A (zh) 2023-08-15
CA3181197A1 (en) 2021-11-04
US20210355211A1 (en) 2021-11-18
IL297748A (en) 2022-12-01
CN115768524A (zh) 2023-03-07
CL2022003004A1 (es) 2023-06-23
ES3039441T3 (en) 2025-10-21
US20240025997A1 (en) 2024-01-25
TW202206463A (zh) 2022-02-16
MX2022013466A (es) 2022-11-16
MY209480A (en) 2025-07-11
EP4691561A2 (en) 2026-02-11
PE20221894A1 (es) 2022-12-13

Similar Documents

Publication Publication Date Title
US12410251B2 (en) ILT-binding agents and methods of use thereof
US10232017B2 (en) Method of treating cancer by administering tumor necrosis factor receptor ligand superfamily (TNFRSF) single-chain polypeptides
US10544219B2 (en) TIGIT-binding agents and uses thereof
US12187796B2 (en) ILT3-binding agents and methods of use thereof
US20180346571A1 (en) Pd-l1-binding agents and uses thereof
WO2018027025A1 (en) Cd40-binding agents and uses thereof
US12240899B2 (en) LAIR-1-binding agents and methods of use thereof
WO2023235706A1 (en) Combination therapies using ilt-binding agents and pd-1 inhibitors
WO2019032945A1 (en) CD40 BINDING AGENT AND USES THEREOF

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221201

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240424

Comment text: Request for Examination of Application